ISA 102

Drug Profile

ISA 102

Alternative Names: Cancer vaccine p53 - ISA Pharmaceutical; ISA-102; P53 Synthetic Long Peptides Vaccine; P53-SLP vaccine

Latest Information Update: 15 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Ovarian cancer

Most Recent Events

  • 15 May 2014 NOT ON COMPANY PIPELINE AND THE LATEST TRIAL WAS NIO. 2013 media releases listed the vaccine in the product summary at the bottom, but vaccine no longer mentioned in 2014 MRs. Assumed discontinued at end of 2013
  • 31 Dec 2013 Discontinued - Phase-I/II for Colorectal cancer in Netherlands (SC)
  • 31 Dec 2013 Discontinued - Phase-II for Ovarian cancer in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top